Pain News and Research

Latest Pain News and Research

CardioGenics announces clinical test sites for QL Care portable blood analyzer

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced the selection of four sites for clinical testing of its patented QL Care™ Analyzer, a portable diagnostic platform designed to produce test results with central lab-like accuracy in 15 minutes using whole blood.

21 Jun 2010

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Boston Scientific Corporation today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. The PolarCath System is used to restore blood flow in patients with critical limb ischemia (severe blockages in the arteries below the knee) and blockages in the femoral and popliteal (behind the knee) arteries. Both conditions result from peripheral artery disease.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

Researchers develop new drugs that relieve cancer pain without side effects

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current pain-treatments like morphine.

21 Jun 2010

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy.

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

Too much tea raises the risk of rheumatoid arthritis: Study

Rheumatoid arthritis (RA) a severely debilitating inflammatory disease of the joints is on the rise worldwide. It leads to severe pain, stiffness, swelling and loss of movement of joints like knees, wrist and even fingers. RA affects women more than men. RA occurs in people who develop a rogue immune system that attacks the tissue that lines the joint cavities called the synovium leading to degeneration of the joints and the symptoms of the disease. In 1995 36.4 per 100,000 women were diagnosed with RA whereas in 2005 the number rose to 54 per 100,000 women.

20 Jun 2010

Lightning Safety Awareness Campaign reduces death and injury from lightning strikes in the U.S.

This year marks the 10th Lightning Safety Awareness Campaign, June 20-26. Spearheaded by the National Weather Service, the campaign has reduced death and injury from lightning strikes in the U.S., with average annual deaths dropping from 72 to 40 in the last decade.

19 Jun 2010

Researchers review data comparing IUDs and hormonal contraceptives

Women who have had intrauterine devices fitted as contraceptives are less likely to become pregnant than those who have hormone injections, a new review by Cochrane Researchers has found. The review, which focused on women in developing countries, also found a possible link between contraceptive method and disease progression in HIV.

19 Jun 2010

Montana Governor visits Cannabis Science's latest acquisition

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to report that Montana Governor Brian Schweitzer visited its latest acquisition, Montana Pain Management in Missoula, yesterday. Governor Schweitzer observed, "You are doing it right."

19 Jun 2010

Akela Pharma first-quarter net loss reduces to $0.4 million

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months ended March 31, 2010.

19 Jun 2010

LUHS opens clinic to treat debilitating effects of CPP in women

Loyola University Health System has opened a clinic to treat the debilitating effects of chronic pelvic pain in women. The clinic is located at the Loyola Outpatient Center at 2160 S. First Ave., in Maywood.

19 Jun 2010

National Cheng Kung University Hospital's Outpatient Building inaugurated

The Outpatient Building of National Cheng Kung University Hospital was officially inaugurated on June 12th to provide excellent medical service and to further ensure the health of people in Southern Taiwan.

18 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

SLE and RA negatively affect patients' emotional relationships, sex lives: Study

Systemic Lupus Erythematosus patients from Brazil and Rheumatoid Arthritis patients from France report that their rheumatic conditions negatively affect their emotional relationships and sex lives, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Two separate studies have shown that vitamin D deficiency is common in patients with a range of rheumatic diseases, with over half of all patients having below the 'normal' healthy levels of vitamin D (48-145 nmol/L) in their bodies. A further study assessing response to vitamin D supplementation found that taking the recommended daily dose did not normalise vitamin D levels in rheumatic disease patients.

18 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

Model Formulary for Children provides information on how to use over 240 essential medicines

The first ever WHO Model Formulary for Children released by the WHO provides information on how to use over 240 essential medicines for treating illness and disease in children from 0 to 12 years of age. This means that for the first time medical practitioners worldwide have access to standardized information on the recommended use, dosage, adverse effects, and contraindications of these medicines for use in children.

18 Jun 2010

Pain News and Research

Latest Pain News and Research

CardioGenics announces clinical test sites for QL Care portable blood analyzer

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

Researchers develop new drugs that relieve cancer pain without side effects

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Too much tea raises the risk of rheumatoid arthritis: Study

Lightning Safety Awareness Campaign reduces death and injury from lightning strikes in the U.S.

Researchers review data comparing IUDs and hormonal contraceptives

Montana Governor visits Cannabis Science's latest acquisition

Akela Pharma first-quarter net loss reduces to $0.4 million

LUHS opens clinic to treat debilitating effects of CPP in women

National Cheng Kung University Hospital's Outpatient Building inaugurated

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

SLE and RA negatively affect patients' emotional relationships, sex lives: Study

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Model Formulary for Children provides information on how to use over 240 essential medicines

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Pain News and Research

Latest Pain News and Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in